Renaissance Technologies
VRAX icon

Renaissance Technologies’s Virax Biolabs VRAX Stock Holding History

Renaissance Technologies’s Portfolio VRAX Stock Details VRAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-5,816
Closed -$282K – 3944
2024
Q3 		$282K Buy
5,816
+5,376
+1,222% +$309K ﹤0.01% 3003
2024
Q2 		$12.8K Buy
+440
New +$10.9K ﹤0.01% 3408
2023
Q3 		– Sell
-98
Closed -$10K – 4149
2023
Q2 		$10K Buy
+98
New +$10.8K ﹤0.01% 3828
2023
Q1 		– Sell
-46
Closed -$8K – 4438
2022
Q4 		$8K Buy
+46
New +$16.3K ﹤0.01% 4046

Other funds holding VRAX

UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
RS
R Squared Central, Hong Kong $182M AUM 18.52% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Northwestern Mutual Wealth Management
Northwestern Mutual Wealth Management Milwaukee, Wisconsin $162B AUM 16.35% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Renaissance Technologies's VRAX Position: Q4 2024 in Review

Renaissance Technologies sold out of Virax Biolabs (VRAX) in Q4 2024, closing a stake of 5,816 shares — an estimated $282K sold.

Renaissance Technologies first reported a position in VRAX in Q4 2022 and held it in 4 quarters. The position peaked at $282K in Q3 2024. 6 funds tracked by Wall St. Rank hold VRAX as of Q4 2024.

  • Renaissance Technologies reported no remaining Virax Biolabs position as of Q4 2024 after selling out during the quarter.
  • Renaissance Technologies sold 5,816 Virax Biolabs shares in Q4 2024, an estimated $282K.
  • Renaissance Technologies first reported a position in Virax Biolabs in Q4 2022 and held it in 4 quarters.
  • Renaissance Technologies's Virax Biolabs position peaked at $282K in Q3 2024.
  • 6 funds tracked by Wall St. Rank held Virax Biolabs as of Q4 2024.

Based on Renaissance Technologies's 13F filing for Q4 2024, filed 13 Feb 2025.